Drug intelligence / Profile preview

SSTX-001

Development stage: Preclinical
Lead developer: Slingshot Therapeutics
Modality: Small Molecules
Administration: Intratumoral

Overview

SSTX-001, also known as Apini, is a preclinical small molecule drug being developed by Slingshot Therapeutics, a company launched by life science investor Syncona. This drug was sourced from the University of Manchester and is intended for the treatment of inflammatory diseases.

Other names: Apini

Targets

NAMPT

Beyond the preview

Go deeper on SSTX-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SSTX-001.

Explore the full profile